Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Osivax logo — Pioneering A New Class of Universal Vaccines

Osivax

Pioneering A New Class of Universal Vaccines

Founded 2017 France France 53 employees Grant Total: $53.30M Biotechnology, Health Care

General Information

Company Name Osivax
Founded Year 2017
Location France France
Founders / Decision Makers
Team member Team member
Employees 53
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Osivax. To contact Osivax, visit osivax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Osivax compare?

A PDF of Osivax and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Osivax soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Osivax

Osivax is a clinical-stage biopharmaceutical company founded in 2017, with its headquarters in France. The company is pioneering a new class of universal vaccines utilizing the oligoDOM® nanoparticle platform technology. Their flagship product, OVX836, a broad-spectrum "universal" influenza candidate, is currently in Phase 2 clinical trials, with over 1200 subjects tested. The $1.50M grant investment received on 05 December 2023 was made by the National Institute of Allergy and Infectious Diseases. Osivax aims to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in a single shot. The company intends to extend its reach to other infectious disease indications through collaborations worldwide.

Business keywords: immunology, vaccine, infectious diseases, pan-respiratory virus, cellular immune response, CD8 T-cell, immuno-oncology, nanoparticle platform technology, clinical-stage biopharmaceutical company, universal vaccines, ovx836, oligODOM, sarbocovirus, clinical trials

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $1.50M 1
National Institute of Allergy and Infectious Diseases
05 Dec 2023
Grant $1.00M 1
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
28 Mar 2023
Grant €10.00M 1
Bpifrance
Bpifrance
23 Jun 2022
Series B €15.00M 2
Anaxago European Innovation Council
Anaxago, European Innovation Council
08 Jul 2020
Grant €15.10M 2
Bpifrance European Innovation Council
Bpifrance, European Innovation Council
08 Jul 2020
Series A €8.00M 3
Anaxago Noshaq
Anaxago, Noshaq +1
10 Jul 2019
Seed Round €2.70M 1
Anaxago
Anaxago
15 Jun 2017

Osivax Alternatives & Competitors

View All Alternatives
Osivax vs
Mucosis
Mucosis

Pioneering needle-free mucosal vaccines for natural and robust immunity.

Venture round
Biotechnology, Health Care
Compare Osivax vs Mucosis
Osivax vs
Novavax
Novavax United States

Powering innovation. Protecting health.

Post-IPO Equity
970 employees
Biotechnology, Health Care
Compare Osivax vs Novavax
Osivax vs
VBI Vaccines Inc.
VBI Vaccines Inc. United States

Driven by Immunology in the Pursuit of Powerful Prevention and Treatment of Disease

Post-IPO Equity
57 employees
Biotechnology, Health Care
Also compare with: Osivax vs Curevo Vaccine Curevo Vaccine View all alternatives

FAQ About Osivax

Pioneering A New Class of Universal Vaccines
Osivax was founded in 2017.
Osivax is headquartered in France.
Osivax operates in Biotechnology and Health Care. Its work centres on immunology, vaccine, infectious diseases and pan-respiratory virus.
Osivax has approximately 53 employees.
Osivax has completed 7 funding rounds, raising a total of $53.30M. The latest funding stage is Grant.
Top alternatives and competitors to Osivax include Mucosis, Novavax, VBI Vaccines Inc., Providence Therapeutics, iTeos Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Osivax and Mucosis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Osivax, https://bouncewatch.com/company/osivax, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes